-
2025-522631-34-00
5
2026-01-14
Osteoarthritis
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-521744-37-00
5
2025-11-17
Mild to moderate major depressive disorder
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-519929-38-00
4
2025-10-27
Metastatic Colorectal Cancer without liver metastases
-
2023-509861-19-01
4
2025-09-30
High-grade B-cell lymphoma (HGBL)
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre